A Phase 2 interventional study of Tesamorelin and Identical Placebo in Non-Alcoholic Fatty Liver Disease, Obesity and Obesity, Abdominal, sponsored by Massachusetts General Hospital. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-11-20.
Sponsored by Massachusetts General Hospital · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Non-alcoholic Fatty Liver Disease by Massachusetts General Hospital — 2 open to participants now, 3 under way, 1 of them phase 3. Non-alcoholic Fatty Liver Disease · Massachusetts General Hospital.
Among the 16 studies in Non-alcoholic Fatty Liver Disease by Massachusetts General Hospital, this one is the 5th largest by enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2019, is one of 3 in phase 2, and was the 9th registered.
1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →2 of the 16 studies in Non-alcoholic Fatty Liver Disease by Massachusetts General Hospital are open now, in 1 country. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 18+
Massachusetts General Hospital
Ages 18–70 · Men only · Healthy volunteers
By country, each count listing its studies:
Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 1
First in 2010; this study’s year is marked. 3 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 51 is below the median of 60 across 1,176 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 40 across the 15 interventional studies, 60 across the 1 observational. Of the 12 that completed or were terminated, 11 (92%) have results posted.
This tab as a report to print or save as PDF → With an account.
Massachusetts General Hospital is the lead sponsor of 2,590 studies on the registry; 447 are open to participants now.
Of its 223 completed or terminated interventional studies of FDA-regulated products, 168 (75%) have results posted.
1 of the studies in Non-alcoholic Fatty Liver Disease by Massachusetts General Hospital that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04833140Phase 3Massachusetts General HospitalEstrogen Administration for the Treatment of NASH in Postmenopausal Women | 2027-07-09 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies in Non-alcoholic Fatty Liver Disease by Massachusetts General Hospital, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Nonalcoholic fatty liver disease (NAFLD) is common in individuals with obesity and is a significant threat to public health, because it can lead to impaired liver function and liver failure. Growth hormone is a hormone produced in the pituitary gland that helps regulate metabolism and growth. Individuals with obesity, on average, secrete less growth hormone than individuals without obesity. There are data to suggest that growth hormone may help to reduce the amount of fat in the liver, and may also reduce inflammation in the liver, both of which would be helpful to individuals with NAFLD. The purpose of this study is to investigate whether treatment with a drug called tesamorelin, which is a growth hormone releasing hormone analogue, will decrease liver fat and improve liver inflammation and scarring in obese individuals with NAFLD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
tesamorelin (brand name Egrifta) 2mg daily given subcutaneously
Drug: Tesamorelin
identical placebo given subcutaneously daily
Drug: Identical Placebo
Tesamorelin F4 formulation 1.4mg daily
Also known as: Egrifta, TH9507, Growth Hormone Releasing Hormone Analog
Placebo injection daily
Liver Fat Content
Liver Fat Content as measured by hydrogen-magnetic resonance spectroscopy. All available data used; data not available for 1 participant in tesamorelin group and 3 participants in placebo group.
Time frame: change from baseline to 12 months
NAFLD Activity Score
Nonalcoholic Fatty Liver Disease Activity Score (NAS, scored between 0-8, with higher indicating more severe disease) from liver biopsy. All available data used; data not available for 3 participants in placebo group and 1 participant in tesamorelin group.
Time frame: change from baseline to 12 months
Low Density Lipoprotein (LDL) Cholesterol
All available data utilized. Data not available for 2 participants in tesamorelin group and 3 participants in placebo group.
Time frame: change from baseline to 12 months
C-reactive Protein
All available data utilized. Data not available for 2 participants in placebo group.
Time frame: change from baseline to 12 months
Fibrosis Score
fibrosis score from liver biopsy; all available data used - data not available for 1 participant in tesamorelin group and 3 participants in placebo group. Fibrosis stage scored from 0-4, where 0 indicates no fibrosis and 4 indicates most severe fibrosis, which is cirrhosis.
Time frame: change from baseline to 12 months
| Milestone | Tesamorelin | Placebo |
|---|---|---|
| Started | 26 | 25 |
| Completed | 19 | 19 |
| Not completed | 7 | 6 |
| Milestone | Tesamorelin | Placebo |
|---|---|---|
| Started | 17 | 13 |
| Completed | 16 | 12 |
| Not completed | 1 | 1 |
Liver Fat Content as measured by hydrogen-magnetic resonance spectroscopy. All available data used; data not available for 1 participant in tesamorelin group and 3 participants in placebo group.
| percent change in hepatic fat fraction | Tesamorelin | Placebo |
|---|---|---|
| Liver Fat Content | -5.3 (-13.0 to -1.4) | 3.6 (-6.2 to 7.9) |
Nonalcoholic Fatty Liver Disease Activity Score (NAS, scored between 0-8, with higher indicating more severe disease) from liver biopsy. All available data used; data not available for 3 participants in placebo group and 1 participant in tesamorelin group.
| units on a scale | Tesamorelin | Placebo |
|---|---|---|
| NAFLD Activity Score | 0 (-2 to 0) | 0 (-1 to 1) |
All available data utilized. Data not available for 2 participants in tesamorelin group and 3 participants in placebo group.
| milligrams per deciliter | Tesamorelin | Placebo |
|---|---|---|
| Low Density Lipoprotein (LDL) Cholesterol | -5.7 ± 27 | -0.7 ± 16 |
All available data utilized. Data not available for 2 participants in placebo group.
| milligrams per liter (mg/L) | Tesamorelin | Placebo |
|---|---|---|
| C-reactive Protein | -0.9 ± 4.2 | 0.0 ± 4.1 |
fibrosis score from liver biopsy; all available data used - data not available for 1 participant in tesamorelin group and 3 participants in placebo group. Fibrosis stage scored from 0-4, where 0 indicates no fibrosis and 4 indicates most severe fibrosis, which is cirrhosis.
| units on a scale | Tesamorelin | Placebo |
|---|---|---|
| Fibrosis Score | 0 (0 to 1) | 0 (0 to 0.5) |
Collected over Adverse events for the double-blind phase occurred during months 0-12 of the study (12-month double-blind phase). Adverse events for the open-label phase occurred during months 12-18 of the study (6-month open label phase that occurred at the end of the 12- month double-blind phase).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Double-blind Phase: Tesamorelin | 0/26 (0%) | 2/26 (7.7%) | 22/26 (84.6%) |
| Double-blind Phase: Placebo | 0/25 (0%) | 3/25 (12%) | 15/25 (60%) |
| Open Label Phase | 0/30 (0%) | 0/30 (0%) | 16/30 (53.3%) |
| Event | Double-blind Phase: Tesamorelin | Double-blind Phase: Placebo | Open Label Phase |
|---|---|---|---|
| rotator cuff surgerySurgical and medical procedures | 0/26 | 1/25 | — |
| appendicitisGastrointestinal disorders | 0/26 | 1/25 | — |
| major depressive disorderPsychiatric disorders | 0/26 | 1/25 | — |
| elective knee replacementSurgical and medical procedures | 1/26 | 0/25 | — |
| liver hematoma following biopsyInjury, poisoning and procedural complications | 1/26 | 0/25 | — |
| Event | Double-blind Phase: Tesamorelin | Double-blind Phase: Placebo | Open Label Phase |
|---|---|---|---|
| Injection site stingingSkin and subcutaneous tissue disorders | 8/26 | 1/25 | 9/30 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 6/26 | 1/25 | 2/30 |
| EdemaSkin and subcutaneous tissue disorders | 6/26 | 1/25 | 1/30 |
| Injection site complaints, otherSkin and subcutaneous tissue disorders | 5/26 | 2/25 | 6/30 |
| Injection site erythemaSkin and subcutaneous tissue disorders | 5/26 | 0/25 | 3/30 |
| Injection site bruisingSkin and subcutaneous tissue disorders | 4/26 | 1/25 | 0/30 |
| HeadacheNervous system disorders | 1/26 | 3/25 | 0/30 |
| Joint painMusculoskeletal and connective tissue disorders | 3/26 | 1/25 | 0/30 |
| GastrointeritisGastrointestinal disorders | 2/26 | 0/25 | 0/30 |
| Injection site itchingSkin and subcutaneous tissue disorders | 2/26 | 0/25 | 0/30 |
| Age, Continuous(years) | Tesamorelin | Placebo | Total |
|---|---|---|---|
| Mean | 47 ± 10 | 47 ± 11 | 47 ± 11 |
| Sex: Female, Male(Participants) | Tesamorelin | Placebo | Total |
|---|---|---|---|
| Female | 12 | 11 | 23 |
| Male | 14 | 14 | 28 |
| Race/Ethnicity, Customized(Participants) | Tesamorelin | Placebo | Total |
|---|---|---|---|
| White | 23 | 15 | 38 |
| Black | 2 | 1 | 3 |
| Other | 0 | 7 | 7 |
| Hispanic ethnicity | 1 | 2 | 3 |
| Region of Enrollment(participants) | Tesamorelin | Placebo | Total |
|---|---|---|---|
| United States | 26 | 25 | 51 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Final Research Data, with all patient identifiers removed, will be available to other researchers through request to the PI. Because information contained in the final research data will include multiple demographic and biological variables that could potentially be used in concert to identify participants, it will be shared only under a Data Sharing Agreement that includes (1) a commitment to using the data only for research purposes and not to identify any individual participant and (2) a commitment to destroying or returning the data after analyses are completed.
Supporting information: Study protocol
Ran from Jan 2019 to primary completion in Jul 2024, 65 months.
Results were first posted in Nov 2025, 1 year 4 months after primary completion.
Of 53 non-industry phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 56. This study's 65 months is above that.
Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tesamorelin
Non-alcoholic Fatty Liver Disease →
Massachusetts General Hospital →